BioCentury | Aug 1, 2020
Translation in Brief

TScan identifies CD8+ T cell COVID-19 epitopes, plus T3 gears up for Phase I of bacterial cancer therapy, a wearable device to monitor PK and a COVID-19 vaccine

SARS-CoV-2 binding sites for cytotoxic T cells  TScan Therapeutics Inc. reported in medRxiv that memory CD8 + T cell responses against SARS-CoV-2 are dominated by a few epitopes in SARS-CoV-2. An analysis of samples from...
BioCentury | Jul 25, 2020
Translation in Brief

New class of cytosine base editors; plus new U.K. vaccine manufacturing facilities, scalable surrogate assay for COVID-19; combating antibiotic resistance and

New base editors widen template-free editing options  A Massachusetts General Hospital team co-led by Beam Therapeutics Inc. (NASDAQ:BEAM) co-founder Keith Joung, and a Chinese Academy of Sciences team have separately developed a new class of...
BioCentury | Jul 22, 2020
Emerging Company Profile

Deep Longevity: Insilico spinout clocks biological age

Insilico spinout Deep Longevity came out of stealth last week with 17 sets of biomarkers, dubbed aging clocks, designed to measure the rate of aging that could be applied to measure treatment efficacy in clinical...
BioCentury | Jul 17, 2020
Emerging Company Profile

Acepodia: linking antitumor antibodies to immune cells

Acepodia is using its antibody-cell conjugation platform to link tumor-targeting antibodies to the surface of cell therapies while avoiding genetic engineering. The platform, which has the potential for cost savings compared with CAR T therapy,...
BioCentury | Jul 17, 2020
Tools & Techniques

Data Bytes: the evolving CRISPR landscape

CRISPR pioneer Jennifer Doudna is adding a Cas protein to the toolbox with features that could make it a good gene editing tool. In a Science paper published on Thursday, the University of California Berkeley...
BioCentury | Jul 17, 2020
Product Development

Dexamethasone included in Novartis’ not-for-profit COVID-19 portfolio

The first therapy to show a mortality benefit in COVID-19 patients, dexamethasone, is among the 15 generic and over-the-counter drugs Novartis plans to provide at zero-profit to up to 79 low- and middle-income countries under...
BioCentury | Jul 9, 2020
Management Tracks

Goeltz to join Arcus as CFO following Gilead deal; plus changes at Corbus, MyoKardia, Humanigen, Aimmune, Avrobio, Syndax and more

Arcus Biosciences Inc. (NYSE:RCUS), named Bob Goeltz as CFO, effective August 1. Goeltz, who was SVP and CFO of Unity Biotechnology Inc. (NASDAQ:UBX), succeeds CFO and COO Rekha Hemrajani. In May, Gilead Sciences Inc. (NASDAQ:GILD)...
BioCentury | Jul 1, 2020
Product Development

Accelerating the fight against COVID-19 with real-world data on tests

Almost every aspect of the fight against COVID-19 depends on the ability to determine whether an individual is or has been infected with SARS-CoV-2, but more than six months into the pandemic there is still...
BioCentury | Jun 27, 2020
Tools & Techniques

Tapping astrocytes to replace lost neurons in Parkinson’s

In the latest example of a regenerative medicine approach that involves transforming one cell type in the body into another, a University of California San Diego team has shown it can replace lost dopamine neurons...
BioCentury | Jun 25, 2020
Emerging Company Profile

Sana’s quest to usher in next generation of cell, gene therapies

With $700 million in its coffers, Sana has broad goals to develop cell and gene therapies that address a wide swath of diseases, with its sights set beyond cancer and rare diseases. While the biotech...
Items per page:
1 - 10 of 2862
BioCentury | Aug 1, 2020
Translation in Brief

TScan identifies CD8+ T cell COVID-19 epitopes, plus T3 gears up for Phase I of bacterial cancer therapy, a wearable device to monitor PK and a COVID-19 vaccine

SARS-CoV-2 binding sites for cytotoxic T cells  TScan Therapeutics Inc. reported in medRxiv that memory CD8 + T cell responses against SARS-CoV-2 are dominated by a few epitopes in SARS-CoV-2. An analysis of samples from...
BioCentury | Jul 25, 2020
Translation in Brief

New class of cytosine base editors; plus new U.K. vaccine manufacturing facilities, scalable surrogate assay for COVID-19; combating antibiotic resistance and

New base editors widen template-free editing options  A Massachusetts General Hospital team co-led by Beam Therapeutics Inc. (NASDAQ:BEAM) co-founder Keith Joung, and a Chinese Academy of Sciences team have separately developed a new class of...
BioCentury | Jul 22, 2020
Emerging Company Profile

Deep Longevity: Insilico spinout clocks biological age

Insilico spinout Deep Longevity came out of stealth last week with 17 sets of biomarkers, dubbed aging clocks, designed to measure the rate of aging that could be applied to measure treatment efficacy in clinical...
BioCentury | Jul 17, 2020
Emerging Company Profile

Acepodia: linking antitumor antibodies to immune cells

Acepodia is using its antibody-cell conjugation platform to link tumor-targeting antibodies to the surface of cell therapies while avoiding genetic engineering. The platform, which has the potential for cost savings compared with CAR T therapy,...
BioCentury | Jul 17, 2020
Tools & Techniques

Data Bytes: the evolving CRISPR landscape

CRISPR pioneer Jennifer Doudna is adding a Cas protein to the toolbox with features that could make it a good gene editing tool. In a Science paper published on Thursday, the University of California Berkeley...
BioCentury | Jul 17, 2020
Product Development

Dexamethasone included in Novartis’ not-for-profit COVID-19 portfolio

The first therapy to show a mortality benefit in COVID-19 patients, dexamethasone, is among the 15 generic and over-the-counter drugs Novartis plans to provide at zero-profit to up to 79 low- and middle-income countries under...
BioCentury | Jul 9, 2020
Management Tracks

Goeltz to join Arcus as CFO following Gilead deal; plus changes at Corbus, MyoKardia, Humanigen, Aimmune, Avrobio, Syndax and more

Arcus Biosciences Inc. (NYSE:RCUS), named Bob Goeltz as CFO, effective August 1. Goeltz, who was SVP and CFO of Unity Biotechnology Inc. (NASDAQ:UBX), succeeds CFO and COO Rekha Hemrajani. In May, Gilead Sciences Inc. (NASDAQ:GILD)...
BioCentury | Jul 1, 2020
Product Development

Accelerating the fight against COVID-19 with real-world data on tests

Almost every aspect of the fight against COVID-19 depends on the ability to determine whether an individual is or has been infected with SARS-CoV-2, but more than six months into the pandemic there is still...
BioCentury | Jun 27, 2020
Tools & Techniques

Tapping astrocytes to replace lost neurons in Parkinson’s

In the latest example of a regenerative medicine approach that involves transforming one cell type in the body into another, a University of California San Diego team has shown it can replace lost dopamine neurons...
BioCentury | Jun 25, 2020
Emerging Company Profile

Sana’s quest to usher in next generation of cell, gene therapies

With $700 million in its coffers, Sana has broad goals to develop cell and gene therapies that address a wide swath of diseases, with its sights set beyond cancer and rare diseases. While the biotech...
Items per page:
1 - 10 of 2862